The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The Chinese biotech will use its proprietary AI-driven drug-delivery platform to develop next-generation technologies aimed at ⁠improving how LNP-based drugs reach target tissues. Sign up here. Metis ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. CEO Dave Ricks built Eli Lilly into the first pharma company to hit a $1 trillion market cap ...

With the Blue Mountain School Board having trouble conducting business due to a lingering vacancy and division among the current directors, a Schuylkill County judge tasked with filling ...

Before I discuss what I do like about Eli Lilly, it is important to also highlight the risks. Pharmaceutical companies without exception face the risk that medical compounds fail to deliver on their ...

TeraWulf agreement could provide an estimated $100 million in winter bill credits for residential customers over 10 years.

People with Type 2 diabetes lost an average of nearly 50 pounds on the highest dose of Eli Lilly's next-generation experimental GLP-1 medication retatrutide, the company said. Lilly said a late-stage ...

Lilly plans to file for FDA approval of retatrutide in the first quarter of next year. (Angus Liu/Fierce Pharma) Eli Lilly has shared detailed data from a phase 3 retatrutide trial, revealing that ...

John Goodman showed off his 200-pound weight loss transformation at the “Digger” premiere in Los Angeles on Monday. The actor, 74, looked sharp in a black suit with a striped shirt and gray tie on the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Eli Lilly and Company (NYSE:LLY)’s CEO David Ricks told CNBC that Foundayo now accounts for roughly one-third of new patients starting an oral GLP-1, with Lilly’s share of the pill market increasing ...

Eli Lilly recently stopped its development of a new GLP-1 weight-loss drug. The company had expectations for the drug's efficacy, and it didn't live up to them. It's unfortunate, but it happens.